Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases

M. Scudeletti, F. Puppo, L. Lanza, L. Mantovani, O. Bosco, A. Iudice, B. Imbimbo, F. Indiveri

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Different glucocorticoid preparations modify the immune reaction in different ways. In this paper, the therapeutic efficacy of two glucocorticoids, deflazacort (DFZ) and prednisone (PDN), are discussed in relation to a group of 30 patients with systemic lupus erythematosus (n = 12) or rheumatoid arthritis (n = 18). The disease subgroups were divided into two arms, one of which was treated with DFZ and one with PDN in a double-blind protocol. The results of this study indicate that DFZ and PDN induced a clinical remission within 1 month which was maintained until the 6th month. Nevertheless, certain immunological modifications, including a significant reduction of the circulating T lymphocyte level and of the CD4/CD8 ratio, which was between 1 and 1,5 during the DFC treatment and between 1 and 2 during the PDN treatment, are more pronounced and more stable with DFZ than with PDN. Moreover, DFZ has a smaller effect on calcium and glucose metabolism than PDN since the serum glucose and calcium level of patients treated with PDN increased respectively from 90 up to 130 mg/dl and from 9,5 to 11,5 mg/dl whereas those of patients treated with DFC remained within the normal range. These findings indicate that DFZ may have advantages over PDN in the treatment of immune-mediated diseases.

Original languageEnglish
JournalEuropean Journal of Clinical Pharmacology
Volume45
Issue number1 Supplement
DOIs
Publication statusPublished - Jan 1993

Fingerprint

Immune System Diseases
Prednisone
Glucocorticoids
Therapeutics
Calcium
Glucose
CD4-CD8 Ratio
deflazacort
Systemic Lupus Erythematosus
Rheumatoid Arthritis
Reference Values
T-Lymphocytes
Serum

Keywords

  • Deflazacort
  • glucocorticoid
  • immune disease
  • Prednisone

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases. / Scudeletti, M.; Puppo, F.; Lanza, L.; Mantovani, L.; Bosco, O.; Iudice, A.; Imbimbo, B.; Indiveri, F.

In: European Journal of Clinical Pharmacology, Vol. 45, No. 1 Supplement, 01.1993.

Research output: Contribution to journalArticle

Scudeletti, M, Puppo, F, Lanza, L, Mantovani, L, Bosco, O, Iudice, A, Imbimbo, B & Indiveri, F 1993, 'Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases', European Journal of Clinical Pharmacology, vol. 45, no. 1 Supplement. https://doi.org/10.1007/BF01844201
Scudeletti, M. ; Puppo, F. ; Lanza, L. ; Mantovani, L. ; Bosco, O. ; Iudice, A. ; Imbimbo, B. ; Indiveri, F. / Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases. In: European Journal of Clinical Pharmacology. 1993 ; Vol. 45, No. 1 Supplement.
@article{2f5efaf9a7a1460b836951f5d9f68a75,
title = "Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases",
abstract = "Different glucocorticoid preparations modify the immune reaction in different ways. In this paper, the therapeutic efficacy of two glucocorticoids, deflazacort (DFZ) and prednisone (PDN), are discussed in relation to a group of 30 patients with systemic lupus erythematosus (n = 12) or rheumatoid arthritis (n = 18). The disease subgroups were divided into two arms, one of which was treated with DFZ and one with PDN in a double-blind protocol. The results of this study indicate that DFZ and PDN induced a clinical remission within 1 month which was maintained until the 6th month. Nevertheless, certain immunological modifications, including a significant reduction of the circulating T lymphocyte level and of the CD4/CD8 ratio, which was between 1 and 1,5 during the DFC treatment and between 1 and 2 during the PDN treatment, are more pronounced and more stable with DFZ than with PDN. Moreover, DFZ has a smaller effect on calcium and glucose metabolism than PDN since the serum glucose and calcium level of patients treated with PDN increased respectively from 90 up to 130 mg/dl and from 9,5 to 11,5 mg/dl whereas those of patients treated with DFC remained within the normal range. These findings indicate that DFZ may have advantages over PDN in the treatment of immune-mediated diseases.",
keywords = "Deflazacort, glucocorticoid, immune disease, Prednisone",
author = "M. Scudeletti and F. Puppo and L. Lanza and L. Mantovani and O. Bosco and A. Iudice and B. Imbimbo and F. Indiveri",
year = "1993",
month = "1",
doi = "10.1007/BF01844201",
language = "English",
volume = "45",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "1 Supplement",

}

TY - JOUR

T1 - Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases

AU - Scudeletti, M.

AU - Puppo, F.

AU - Lanza, L.

AU - Mantovani, L.

AU - Bosco, O.

AU - Iudice, A.

AU - Imbimbo, B.

AU - Indiveri, F.

PY - 1993/1

Y1 - 1993/1

N2 - Different glucocorticoid preparations modify the immune reaction in different ways. In this paper, the therapeutic efficacy of two glucocorticoids, deflazacort (DFZ) and prednisone (PDN), are discussed in relation to a group of 30 patients with systemic lupus erythematosus (n = 12) or rheumatoid arthritis (n = 18). The disease subgroups were divided into two arms, one of which was treated with DFZ and one with PDN in a double-blind protocol. The results of this study indicate that DFZ and PDN induced a clinical remission within 1 month which was maintained until the 6th month. Nevertheless, certain immunological modifications, including a significant reduction of the circulating T lymphocyte level and of the CD4/CD8 ratio, which was between 1 and 1,5 during the DFC treatment and between 1 and 2 during the PDN treatment, are more pronounced and more stable with DFZ than with PDN. Moreover, DFZ has a smaller effect on calcium and glucose metabolism than PDN since the serum glucose and calcium level of patients treated with PDN increased respectively from 90 up to 130 mg/dl and from 9,5 to 11,5 mg/dl whereas those of patients treated with DFC remained within the normal range. These findings indicate that DFZ may have advantages over PDN in the treatment of immune-mediated diseases.

AB - Different glucocorticoid preparations modify the immune reaction in different ways. In this paper, the therapeutic efficacy of two glucocorticoids, deflazacort (DFZ) and prednisone (PDN), are discussed in relation to a group of 30 patients with systemic lupus erythematosus (n = 12) or rheumatoid arthritis (n = 18). The disease subgroups were divided into two arms, one of which was treated with DFZ and one with PDN in a double-blind protocol. The results of this study indicate that DFZ and PDN induced a clinical remission within 1 month which was maintained until the 6th month. Nevertheless, certain immunological modifications, including a significant reduction of the circulating T lymphocyte level and of the CD4/CD8 ratio, which was between 1 and 1,5 during the DFC treatment and between 1 and 2 during the PDN treatment, are more pronounced and more stable with DFZ than with PDN. Moreover, DFZ has a smaller effect on calcium and glucose metabolism than PDN since the serum glucose and calcium level of patients treated with PDN increased respectively from 90 up to 130 mg/dl and from 9,5 to 11,5 mg/dl whereas those of patients treated with DFC remained within the normal range. These findings indicate that DFZ may have advantages over PDN in the treatment of immune-mediated diseases.

KW - Deflazacort

KW - glucocorticoid

KW - immune disease

KW - Prednisone

UR - http://www.scopus.com/inward/record.url?scp=0027445471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027445471&partnerID=8YFLogxK

U2 - 10.1007/BF01844201

DO - 10.1007/BF01844201

M3 - Article

C2 - 8313931

AN - SCOPUS:0027445471

VL - 45

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 1 Supplement

ER -